Johnson & Johnson to buy Firefly Bio for $1 billion

Johnson & Johnson agreed to pay $1 billion in cash for Firefly Bio, betting that a young platform company can help refill an oncology pipeline built around some of cancer medicine’s hardest targets. The acquisition centers on Firefly’s Firelink system, a degrader antibody conjugate platform that J&J says could push more precise treatment into tumors driven by KRAS and other difficult cancer drivers.

The companies said June 8, 2026, that they had entered into a definitive agreement. Closing is expected later in 2026, pending regulatory approvals and other customary conditions. For J&J, the deal adds another piece to a broader push into targeted cancer medicine, especially in the most prevalent solid tumors where unmet need remains high and where pan-KRAS has become one of the most closely watched opportunities in oncology.

Firefly’s technology is designed to combine the targeting precision of antibody-drug conjugates with selective protein degraders. Reuters described the Firelink platform as using antibodies to deliver a protein-degrading drug directly into cancer cells, an approach intended to attack tumors while sparing more healthy tissue than some existing therapies. The appeal is clear, but the distance to commercial payoff is equally clear: Firefly was founded in 2022, emerged from stealth in February 2024 with a $94 million Series A financing, and has yet to reach the stage where the market can judge a commercial product rather than a scientific platform. Its founders include Carolyn Bertozzi, John Flygare and Bernhard Geierstanger, while company materials list Scott Hirsch as chief executive and Dan Kaplan as chief scientific officer.

That makes the purchase look less like a simple product acquisition and more like strategic optionality. J&J is buying a technology stack that could support multiple future programs if the science continues to hold up, not just one drug candidate. Firefly’s own backers include Versant Ventures, MPM BioImpact, Decheng Capital and Eli Lilly & Company, underscoring the degree of outside interest in the approach before J&J stepped in.

The deal also fits J&J’s recent pattern in oncology. In 2025, the company agreed to buy Halda Therapeutics for $3.05 billion in cash, another sign that cancer remains one of the company’s most active hunt zones. The latest move comes as renewed enthusiasm around KRAS-targeted therapies, including data from Revolution Medicines, has sharpened competition for assets that could work against a notoriously stubborn set of mutations. For J&J, Firefly is a wager on whether a promising platform can become a durable source of new cancer drugs before rivals close in.